MX2022003367A - Polipeptidos moduladores de linfocitos t y metodos de uso de estos. - Google Patents
Polipeptidos moduladores de linfocitos t y metodos de uso de estos.Info
- Publication number
- MX2022003367A MX2022003367A MX2022003367A MX2022003367A MX2022003367A MX 2022003367 A MX2022003367 A MX 2022003367A MX 2022003367 A MX2022003367 A MX 2022003367A MX 2022003367 A MX2022003367 A MX 2022003367A MX 2022003367 A MX2022003367 A MX 2022003367A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- lymphocyte
- methods
- cell
- modulating
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 229940125750 lymphocyte modulator Drugs 0.000 title 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962903441P | 2019-09-20 | 2019-09-20 | |
| US202062990693P | 2020-03-17 | 2020-03-17 | |
| US202063048561P | 2020-07-06 | 2020-07-06 | |
| PCT/US2020/051255 WO2021055594A1 (en) | 2019-09-20 | 2020-09-17 | T-cell modulatory polypeptides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003367A true MX2022003367A (es) | 2022-04-11 |
Family
ID=74884186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003367A MX2022003367A (es) | 2019-09-20 | 2020-09-17 | Polipeptidos moduladores de linfocitos t y metodos de uso de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220143063A1 (enExample) |
| EP (1) | EP4030897A4 (enExample) |
| JP (1) | JP7756072B2 (enExample) |
| KR (1) | KR20220066075A (enExample) |
| CN (1) | CN114423284A (enExample) |
| AU (1) | AU2020348373A1 (enExample) |
| CA (1) | CA3146591A1 (enExample) |
| IL (1) | IL290635A (enExample) |
| MX (1) | MX2022003367A (enExample) |
| TW (1) | TW202126683A (enExample) |
| WO (1) | WO2021055594A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| WO2021087840A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| US11058751B1 (en) * | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| WO2022140759A2 (en) * | 2020-12-23 | 2022-06-30 | Janssen Biotech, Inc. | Neoantigen peptide mimics |
| EP4308143A4 (en) * | 2021-03-19 | 2025-06-04 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| EP4504802A4 (en) * | 2022-04-07 | 2026-03-25 | Cue Biopharma Inc | IMMUNE CELL BINDING POLYPEPTIDES |
| CN115820736B (zh) * | 2022-12-08 | 2024-05-10 | 西南大学 | 家蚕丝胶蛋白Ser4在提高蚕丝性能中的应用及其方法 |
| WO2024264007A2 (en) * | 2023-06-23 | 2024-12-26 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| WO2024264004A2 (en) * | 2023-06-23 | 2024-12-26 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| WO2026125765A1 (en) | 2024-12-13 | 2026-06-18 | Immunoscape Pte. Ltd. | Combination therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6652932B2 (ja) * | 2014-06-18 | 2020-02-26 | アルバート アインシュタイン カレッジ オブ メディシン | ｓｙｎＴａｃポリペプチド及びその使用 |
| EP3286222A4 (en) | 2015-03-23 | 2018-08-08 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| RU2018130525A (ru) * | 2016-01-27 | 2020-02-27 | Цсл Беринг Ленгнау Аг | РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG |
| CA3014458A1 (en) * | 2016-03-02 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2017151940A2 (en) * | 2016-03-03 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| SG11201808552XA (en) * | 2016-05-18 | 2018-10-30 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN110325205B (zh) * | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) * | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR20240005989A (ko) * | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| WO2019051127A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2019139896A1 (en) * | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| KR20230009426A (ko) | 2020-05-12 | 2023-01-17 | 스미토모 파마 가부시키가이샤 | 암을 처치하기 위한 의약 조성물 |
-
2020
- 2020-09-17 EP EP20865317.0A patent/EP4030897A4/en active Pending
- 2020-09-17 MX MX2022003367A patent/MX2022003367A/es unknown
- 2020-09-17 CN CN202080065140.0A patent/CN114423284A/zh active Pending
- 2020-09-17 WO PCT/US2020/051255 patent/WO2021055594A1/en not_active Ceased
- 2020-09-17 KR KR1020227009918A patent/KR20220066075A/ko not_active Withdrawn
- 2020-09-17 JP JP2022506595A patent/JP7756072B2/ja active Active
- 2020-09-17 AU AU2020348373A patent/AU2020348373A1/en not_active Abandoned
- 2020-09-17 CA CA3146591A patent/CA3146591A1/en active Pending
- 2020-09-18 TW TW109132369A patent/TW202126683A/zh unknown
-
2022
- 2022-01-25 US US17/584,133 patent/US20220143063A1/en not_active Abandoned
- 2022-02-15 IL IL290635A patent/IL290635A/en unknown
-
2024
- 2024-10-01 US US18/903,947 patent/US20250120996A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7756072B2 (ja) | 2025-10-17 |
| US20220143063A1 (en) | 2022-05-12 |
| EP4030897A4 (en) | 2023-10-18 |
| IL290635A (en) | 2022-04-01 |
| KR20220066075A (ko) | 2022-05-23 |
| WO2021055594A1 (en) | 2021-03-25 |
| EP4030897A1 (en) | 2022-07-27 |
| US20250120996A1 (en) | 2025-04-17 |
| CN114423284A (zh) | 2022-04-29 |
| CA3146591A1 (en) | 2021-03-25 |
| JP2022548472A (ja) | 2022-11-21 |
| AU2020348373A1 (en) | 2022-02-24 |
| TW202126683A (zh) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007287A (es) | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. | |
| MX2020002596A (es) | Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. | |
| MX2021014476A (es) | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. | |
| CO2020012584A2 (es) | Suministro intracelular de biomoléculas para modificar respuestas inmunes | |
| CL2020001451A1 (es) | Proteínas modificadas de unión a adn. | |
| MX2021007479A (es) | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. | |
| CL2021001744A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324) | |
| CL2023001860A1 (es) | Composiciones y métodos para reducir hla-a en una célula | |
| CL2021002147A1 (es) | Células asesinas naturales (nk) modificadas para inmunoterapia | |
| MX2021007556A (es) | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. | |
| PH12019502276A1 (en) | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use | |
| MX2020007046A (es) | Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales. | |
| BR112019012964A2 (pt) | polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos | |
| WO2022197970A3 (en) | T-cell modulatory polypeptides and methods of use thereof | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| MX2017001062A (es) | Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso. | |
| AU2018289493A1 (en) | Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction | |
| PE20191324A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| IL289829A (en) | Immunomodulatory antibodies and methods of use thereof | |
| MX395037B (es) | Dispositivo de elevacion de huevos y sistemas y metodos de transferencia relacionados | |
| MX2021005540A (es) | Peptidos inmunogenicos con motivos de oxidorreductasa mejorados. | |
| ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
| MX2016009911A (es) | Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes. | |
| AR115537A1 (es) | Terapia combinada con una vacuna neoantigénica | |
| MX2020005836A (es) | Controles sinteticos para inmunohistoquimica. |